Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 3/20 | 0.69 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.54 |
| ▸ | RET | P07949 | 2/20 | 0.52 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.52 |
| ▸ | KIT | P10721 | 2/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.47 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.47 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.47 |
| ▸ | RORC | P51449 | 1/20 | 0.47 |
| ▸ | STK10 | O94804 | 1/20 | 0.47 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.47 |
| ▸ | CSF1R | P07333 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12912594 | 1.00 | PDGFRB (0.69) | PDGFRBERBB2RETFGFR1KIT | |
| SCHEMBL1248149 | 1.00 | PDGFRB (0.69) | PDGFRBERBB2RETFGFR1KIT | |
| SCHEMBL4995844 | 0.90 | ERBB2 (0.66) | PDGFRBERBB2RETFGFR1KIT | |
| SCHEMBL4995840 | 0.90 | ERBB2 (0.66) | PDGFRBERBB2RETFGFR1KIT | |
| SCHEMBL4989003 | 0.89 | ERBB2 (0.68) | PDGFRBERBB2RETFGFR1KIT | |
| SCHEMBL4992761 | 0.89 | ERBB2 (0.68) | PDGFRBERBB2RETFGFR1KIT | |
| SCHEMBL3574920 | 0.89 | PDGFRB (0.54) | PDGFRBERBB2RETRPS6KA3RPS6KA2 | |
| SCHEMBL3574918 | 0.89 | PDGFRB (0.54) | PDGFRBERBB2RETRPS6KA3RPS6KA2 | |
| SCHEMBL4999289 | 0.89 | ERBB2 (0.68) | PDGFRBERBB2RETFGFR1KIT | |
| SCHEMBL4999287 | 0.89 | ERBB2 (0.68) | PDGFRBERBB2RETFGFR1KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105031-A1 | METHOD FOR PREDICTION OF THE EFFICACY OF VASCULARIZATION INHIBITOR | ESAI R & D MANAGEMENT CO., LTD. (JP) | 2010-04-29 | — | — | US | claimed |
| US-20100092490-A1 | METHOD FOR ASSAY ON THE EFFECT OF VASCULARIZATION INHIBITOR | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-04-15 | — | — | US | claimed |
| US-7414054-B2 | 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. (US) | 2008-08-19 | — | — | US | claimed |
| EP-1925676-A1 | METHOD FOR ASSAY ON THE EFFECT OF VASCULARIZATION INHIBITOR | Eisai R&D Management Co., Ltd. (JP) | 2008-05-28 | — | — | EP | claimed |
| EP-1925941-A1 | METHOD FOR PREDICTION OF THE EFFICACY OF VASCULARIZATION INHIBITOR | Eisai R&D Management Co., Ltd. (JP) | 2008-05-28 | — | — | EP | claimed |
| US-20210121397-A1 | BIODEGRADABLE INTRAVITREAL TYROSINE KINASE IMPLANTS | ALLERGAN INC (US) | 2021-04-29 | — | — | US | disclosed |
| US-10881608-B2 | Biodegradable intravitreal tyrosine kinase implants | ALLERGAN, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-20200199689-A1 | Method for Predicting Effectiveness of Angiogenesis Inhibitor | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-06-25 | — | — | US | disclosed |
| US-20190038551-A1 | BIODEGRADABLE INTRAVITREAL TYROSINE KINASE IMPLANTS | ALLERGAN, INC. | 2019-02-07 | — | — | US | disclosed |
| US-10076492-B2 | Biodegradable intravitreal tyrosine kinase implants | ALLERGAN, INC. (US) | 2018-09-18 | — | — | US | disclosed |
| US-20170191137-A1 | Method For Predicting Effectiveness Of Angiogenesis Inhibitor | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2017-07-06 | — | — | US | disclosed |
| US-20160199297-A1 | BIODEGRADABLE INTRAVITREAL TYROSINE KINASE IMPLANTS | ALLERGAN, INC. | 2016-07-14 | — | — | US | disclosed |
| WO-2005107708-A1 | BIODEGRADABLE INTRAVITREAL TYROSINE KINASE INHIBITORS IMPLANTS | ALLERGAN, INC. (US) | 2005-11-17 | — | — | WO | disclosed |
| US-20050244475-A1 | Biodegradable intravitreal tyrosine kinase implants | ALLERGAN, INC. (US) | 2005-11-03 | — | — | US | disclosed |
| US-20050244470-A1 | Producing eye insertable drug delivery agent; extruding active ingredient with polyvinyl alcohol free biodegradable polymer; pharmacokinetics | ALLERGAN, INC. (US) | 2005-11-03 | — | — | US | disclosed |
| US-20050244477-A1 | Tyrosine kinase microsphers | ALLERGAN, INC. (US) | 2005-11-03 | — | — | US | disclosed |
| US-20040198802-A1 | Kinase inhibitors for the treatment of disease | ALLERGAN, INC. | 2004-10-07 | — | — | US | disclosed |
| US-6747025-B1 | TREATING DISEASES RELATED TO UNREGULATED TYROSINE KINASE SIGNAL TRANSDUCTION; ANTIPROLIFERATIVE AGENTS | ALLERGAN, INC. | 2004-06-08 | — | — | US | disclosed |
| US-20040102509-A1 | KINASE INHIBITORS FOR THE TREATMENT OF DISEASE | ALLERGAN, INC. | 2004-05-27 | — | — | US | disclosed |
| US-6699863-B1 | REGULATE, MODULATE AND/OR INHIBIT ABNORMAL CELL PROLIFERATION. | ALLERGAN, INC. | 2004-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10076492-B2 | Biodegradable intravitreal tyrosine kinase implants | KDR, PTK2B, DSTYK | PDGFRB 181/4885ERBB2 7/4885RET 11/4885 |
| US-20050244470-A1 | Producing eye insertable drug delivery agent; extruding active ingredient with polyvinyl alcohol free biodegradable polymer; pharmacokinetics | KDR, ERBB2, ALK | PDGFRB 236/4885ERBB2 2/4885RET 36/4885 |
| US-20040198802-A1 | Kinase inhibitors for the treatment of disease | ABL1, ERBB2, LCK | PDGFRB 282/4885ERBB2 2/4885RET 10/4885 |
| US-20210121397-A1 | BIODEGRADABLE INTRAVITREAL TYROSINE KINASE IMPLANTS | KDR, PTK2B, DSTYK | PDGFRB 181/4885ERBB2 7/4885RET 11/4885 |
| US-20040102509-A1 | KINASE INHIBITORS FOR THE TREATMENT OF DISEASE | ABL1, ERBB2, LCK | PDGFRB 282/4885ERBB2 2/4885RET 10/4885 |
| US-10881608-B2 | Biodegradable intravitreal tyrosine kinase implants | KDR, PTK2B, DSTYK | PDGFRB 181/4885ERBB2 7/4885RET 11/4885 |
| US-20200199689-A1 | Method for Predicting Effectiveness of Angiogenesis Inhibitor | VEGFA, BRAF, FLT4 | PDGFRB 84/4885ERBB2 206/4885RET 397/4885 |
| US-20100092490-A1 | METHOD FOR ASSAY ON THE EFFECT OF VASCULARIZATION INHIBITOR | VEGFA, FLT4, MKI67 | PDGFRB 51/4885ERBB2 34/4885RET 1219/4885 |
| US-20160199297-A1 | BIODEGRADABLE INTRAVITREAL TYROSINE KINASE IMPLANTS | KDR, PTK2B, DSTYK | PDGFRB 179/4885ERBB2 7/4885RET 11/4885 |
| US-20190038551-A1 | BIODEGRADABLE INTRAVITREAL TYROSINE KINASE IMPLANTS | KDR, PTK2B, DSTYK | PDGFRB 179/4885ERBB2 7/4885RET 11/4885 |
| US-20170191137-A1 | Method For Predicting Effectiveness Of Angiogenesis Inhibitor | VEGFA, BRAF, FLT4 | PDGFRB 84/4885ERBB2 206/4885RET 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.